Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | TYR | P14679 | 1/20 | 0.38 |
| ▸ | PRNP | P04156 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12082438 | 0.78 | MEN1 (0.47) | ESR1ESR2MEN1KMT2AALDH1A1 | |
| SCHEMBL2957574 | 0.74 | ALDH1A1 (0.46) | ESR1ESR2MEN1KMT2AALDH1A1 | |
| SCHEMBL3287647 | 0.74 | ESR2 (0.45) | ESR1ESR2MEN1KMT2AALDH1A1 | |
| SCHEMBL9283252 | 0.73 | MEN1 (0.47) | ESR1ESR2MEN1KMT2AALDH1A1 | |
| SCHEMBL14086693 | 0.71 | MEN1 (0.46) | ESR1ESR2MEN1KMT2AALDH1A1 | |
| SCHEMBL27973276 | 0.71 | MEN1 (0.58) | ESR1ESR2MEN1KMT2AALDH1A1 | |
| SCHEMBL17037387 | 0.71 | MEN1 (0.46) | ESR1ESR2MEN1KMT2AALDH1A1 | |
| SCHEMBL26778287 | 0.68 | STS (0.56) | ESR1ESR2MEN1KMT2AALDH1A1 | |
| SCHEMBL26778285 | 0.68 | STS (0.56) | ESR1ESR2MEN1KMT2AALDH1A1 | |
| SCHEMBL26778284 | 0.67 | STS (0.58) | ESR1ESR2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9884839-B2 | Inhibitors of 17Beta-hydroxysteroid dehydrogenases type 1 and type 2 | ELEXOPHARM GMBH (DE) | 2018-02-06 | — | — | US | disclosed |
| US-9884839-B2 | Inhibitors of 17Beta-hydroxysteroid dehydrogenases type 1 and type 2 | ELEXOPHARM GMBH (DE) | 2018-02-06 | — | — | US | disclosed |
| US-20160318895-A1 | Inhibitors of 17Beta-Hydroxysteroid Dehydrogenases Type 1 and Type 2 | ELEXOPHARM GMBH (DE) | 2016-11-03 | — | — | US | disclosed |
| US-20160318895-A1 | Inhibitors of 17Beta-Hydroxysteroid Dehydrogenases Type 1 and Type 2 | ELEXOPHARM GMBH (DE) | 2016-11-03 | — | — | US | disclosed |
| US-20080293683-A1 | Hormone Replacement Therapy | UNIVERSITY OF KANSAS MEDICAL CENTER (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293683-A1 | Hormone Replacement Therapy | UNIVERSITY OF KANSAS MEDICAL CENTER (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080234238-A1 | PHARMACEUTICAL PRODUCT CONTAINING PROGESTIN, GENISTEIN, AND VITAMIN D COMPOUND | RODRIGUEZ GUSTAVO C | 2008-09-25 | — | — | US | disclosed |
| US-20080234238-A1 | PHARMACEUTICAL PRODUCT CONTAINING PROGESTIN, GENISTEIN, AND VITAMIN D COMPOUND | RODRIGUEZ GUSTAVO C | 2008-09-25 | — | — | US | disclosed |
| US-20080045488-A1 | PREVENTION OF OVARIAN CANCER BY ADMINISTRATION OF PRODUCTS THAT INDUCE BIOLOGICAL EFFECTS IN THE OVARIAN EPITHELIUM | NEW LIFE PHARMACEUTICALS INC. (US) | 2008-02-21 | — | — | US | disclosed |
| US-20080045488-A1 | PREVENTION OF OVARIAN CANCER BY ADMINISTRATION OF PRODUCTS THAT INDUCE BIOLOGICAL EFFECTS IN THE OVARIAN EPITHELIUM | NEW LIFE PHARMACEUTICALS INC. (US) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318895-A1 | Inhibitors of 17Beta-Hydroxysteroid Dehydrogenases Type 1 and Type 2 | HSD17B1, HSD17B2, HSD17B3 | ESR1 1117/4885ESR2 201/4885MEN1 2393/4885 |
| US-20080234238-A1 | PHARMACEUTICAL PRODUCT CONTAINING PROGESTIN, GENISTEIN, AND VITAMIN D COMPOUND | CYP24A1, VDR, CYP2R1 | ESR1 63/4885ESR2 69/4885MEN1 257/4885 |
| US-20080045488-A1 | PREVENTION OF OVARIAN CANCER BY ADMINISTRATION OF PRODUCTS THAT INDUCE BIOLOGICAL EFFECTS IN THE OVARIAN EPITHELIUM | TGFB1, HDGF, TGFB2 | ESR1 616/4885ESR2 28/4885MEN1 3618/4885 |
| US-20080293683-A1 | Hormone Replacement Therapy | ESR2, SHBG, ESRRG | ESR1 4/4885ESR2 1/4885MEN1 2282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.